Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 152Diabetes Treatment and ManagementPharmacology and Obesity TreatmentMedication Adherence and Compliance

The DOI matches its Crossref record; 30 of the 32 references it cites were found in a registry or an index; 22 of the 33 sources its claims cite were checked for support.

Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK

Open access

Abstract

This retrospective UK cohort study assessed weight change, adherence, and discontinuation among patients with T2D initiating injectable GLP-1 RAs.

Overview

CoChat Summary

## TL;DR

This retrospective cohort study of 589 UK patients with type 2 diabetes starting injectable GLP-1 receptor agonists found that real-world weight loss was modest and adherence was only moderate. By 24 months, 43.5% of patients with weight data lost at least 5% of baseline weight, while 59.2% were adherent and 64.7% had discontinued therapy.

## Key findings

  • Among patients with weight measures available, 33.4% achieved clinically meaningful weight loss (≥5% of baseline weight) at 12 months and 43.5% at 24 months; mean weight change was −4.6 kg at 12 months and −5.2 kg at 24 months.
  • Adherence declined from 64.5% at 12 months to 59.2% at 24 months (PDC ≥0.80 among patients with at least two fills).
  • Discontinuation was common: 45.2% at 12 months and 64.7% at 24 months, with a median time to discontinuation of 426 days (95% CI 384 to 476).
  • Weekly dosing was associated with higher adherence but also higher discontinuation in adjusted models; at 24 months, 74.1% of weekly-dose patients were adherent versus 55.3% of daily-dose patients, while 76.6% of weekly-dose patients discontinued versus 61.5% of daily-dose patients.

## Methods

  • Retrospective cohort study using the UK Clinical Practice Research Datalink (CPRD), spanning January 1, 2009 to December 31, 2017.
  • Included 589 adults (≥18 years) with type 2 diabetes who initiated injectable GLP-1 RA monotherapy or GLP-1 RA plus metformin after a 12-month baseline period; weight analysis used patients with available weight measures, and adherence analysis required at least two GLP-1 RA fills.
  • Main analyses were descriptive summaries plus bivariate and multivariable logistic regression for adherence/discontinuation, and Kaplan-Meier analysis for time to discontinuation; adherence was defined as PDC ≥0.80 and discontinuation as a >90-day gap between prescriptions.

## Limitations

  • The paper states sample sizes were relatively small (589 total; 530 for adherence), and eligibility restrictions to avoid other antihyperglycemic agents reduced generalizability to the broader T2DM population.
  • Weight data were available for only a fraction of the cohort, and the authors note the impact of lifestyle modifications on weight could not be ascertained.
  • The paper says observational confounding may have influenced results; additionally, baseline comorbidities may be under-reported because they depended on Read codes, and findings may not apply to oral GLP-1 RAs or other populations.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1136/bmjdrc-2021-002517

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Per cent of patients who were adherent to (n=530)† and discontinued (n=589) GLP-1 RA therapy at 12 and 24 months. †Adherence assessed among patients with two or more GLP-1 RA prescriptions. BMI, body mass index; GLP-1 RA, glucagon-like peptide-1 receptor agonist.
Figure 1 Per cent of patients who were adherent to (n=530)† and discontinued (n=589) GLP-1 RA therapy at 12 and 24 months. †Adherence assessed among patients with two or more GLP-1 RA prescriptions. BMI, body mass index; GLP-1 RA, glucagon-like peptide-1 receptor agonist.CC BY-NC · PubMed Central
Figure 2 Time to discontinuation of GLP-1 RAs, Kaplan-Meier plot, n=589. Patients discontinued a median of 426 days (95% CI 384 to 474) after initiating GLP-1 RA therapy.GLP-1 RA, glucagon-like peptide-1 receptor agonist.
Figure 2 Time to discontinuation of GLP-1 RAs, Kaplan-Meier plot, n=589. Patients discontinued a median of 426 days (95% CI 384 to 474) after initiating GLP-1 RA therapy.GLP-1 RA, glucagon-like peptide-1 receptor agonist.CC BY-NC · PubMed Central

Verification

Claims the paper makes

12 Valid · 3 Not valid · 4 Not checked · 41 Own results and interpretations

19 more claims · 4 with their cited sources checked

Create a free account to see all 60 claims and to verify the 1 reference still open.

See all claims — free account
  • It may state two separate claims as one. 22
  • Probably not a substantial claim. 13
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 32 references

Cited by

See all 152

Metadata

Authors
Weiss, T., Yang, L., Carr, R. D., Pal, S., Sawhney, B., Boggs, R., Rajpathak, S., & Iglay, K.
Affiliations
  • Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
  • Complete HEOR Solutions, North Wales, Pennsylvania, USA
Corresponding author
Weiss, Tracey
Venue
BMJ Open Diabetes Research & Care
Publisher
BMJ
Published
2022-01
Volume
10
Issue
1
Pages
e002517
ISSN
2052-4897 (ISSN-L)
OpenAlex
W4210809516
Cited by
152
References
32
Citations by year
2026: 32 · 2025: 48 · 2024: 48 · 2023: 16 · 2022: 8
FWCI
22.41
Type
journal article
Language
en
Open access
Locations
  • BMJ Open Diabetes Research & Care (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Merck Sharp and Dohme (n/a)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
Keywords
GLP-1 receptor agonists, type 2 diabetes, weight loss, medication adherence, treatment discontinuation, proportion of days covered, real-world effectiveness
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Female, United Kingdom, Humans, Hypoglycemic Agents, Middle Aged, Retrospective Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK. https://app.cochat.ai/papers/10.1136/bmjdrc-2021-002517
The paper
Weiss, T., Yang, L., Carr, R. D., Pal, S., Sawhney, B., Boggs, R., Rajpathak, S., & Iglay, K. (2022). Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK. BMJ Open Diabetes Research & Care. https://doi.org/10.1136/bmjdrc-2021-002517

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.